China Pharma E-Commerce Set For Tighter Regulation As Models Shift
This article was originally published in PharmAsia News
China is set to formulate more policies and standards for its booming pharmaceutical e-commence sector after the issuance of draft supervision and administration of online drug business operations last year. Prescription drugs and health insurance systems are the biggest obstacles that need to be faced.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.